ADAG

Adagene Inc.

1.51 USD

Last updated Dec 8, 15:23 UTC

Yesterday HIGH

$1.97

Yesterday LOW

$1.8

52w HIGH

$2.1

52w LOW

$1.01

EPS

0

PE

0.00

Next Earnings

Mar 26, 2024

Overview News Government Trades

Adagene Inc. stock is up 8.63% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.

Stock Exchange

-

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

Benzinga Insights

Thu Dec 22, 2022

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Lisa Levin

Fri Dec 16, 2022

Why Avaya Holdings Shares Are Trading Lower By 62%? Here Are 62 Stocks Moving In Friday's Mid-Day Session

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) gained 240% to $0.90. Allarity Therapeutics, last month, posted a Q3 loss of $0.68 per share.
Benzinga Insights

Fri Dec 16, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Bill Haddad

Fri Dec 16, 2022

Adagene Announces Clinical Trial Collaboration To Evaluate Anti-CTLA-4 SAFEbody ADG126 In Combination With Roche's Standard-of-Care for First-Line Advanced Liver Cancer
Benzinga Newsdesk

Wed Dec 7, 2022

HC Wainwright & Co. Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $5

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $5.
Benzinga Insights

Tue Oct 25, 2022

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 120 companies set new 52-week lows.
Benzinga Insights

Tue Oct 25, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers
Benzinga Newsdesk

Tue Oct 11, 2022

Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming Society For Immunotherapy Of Cancer's Annual Meeting in November

- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated
Charles Gross

Mon Sep 12, 2022

Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors

Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.
Benzinga Newsdesk

Fri Sep 9, 2022

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7

Morgan Stanley analyst Matthew Harrison maintains Adagene (NASDAQ:ADAG) with a Overweight and lowers the price target from $15 to $7.

LULU $477.98 USD

EVRI $10.49 USD

CRSP $74.14 USD

FSLR $149.17 USD

PARA $16.74 USD

BRLI BRLI $10.20 USD

AVGO $924.12 USD

AAMC AAMC $5.21 USD